

Cover Story
Conversation with The Cancer LetterReal-world Evidence
The U.S. Supreme Court’s June 2022 decision to overturn Roe v. Wade has implications that reach far beyond access to reproductive health care services in the 41 states that ban or restrict access to abortion.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- Preparing to take care of each other in ways we never imagined
- From the chairs of ECOG-ACRIN: A perspective on indirect costs
- FDA grants Cytotron Breakthrough Device Designation for breast, liver and pancreatic cancers
- On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centers
The Cancer Letter’s new podcast offers insight into cancer policy in a landscape of uncertainty - “The Agency finds you are not fit…”
HHS notifications of firing add insult to injury - As cancer research is threatened, we must engage in political advocacy